779 results match your criteria: "centre de recherche en neurosciences de Lyon[Affiliation]"

The "bouba-kiki effect", where "bouba" is perceived round and "kiki" spiky, remains a puzzling enigma. We solve it by combining mathematical findings largely unknown in the field, with computational models and novel experimental evidence. We reveal that this effect relies on two acoustic cues: spectral balance and temporal continuity.

View Article and Find Full Text PDF

From observations in rodents, it has been suggested that the cellular basis of learning-dependent changes, detected using structural MRI, may be increased dendritic spine density, alterations in astrocyte volume, and adaptations within intracortical myelin. Myelin plasticity is crucial for neurological function, and active myelination is required for learning and memory. However, the dynamics of myelin plasticity and how it relates to morphometric-based measurements of structural plasticity remains unknown.

View Article and Find Full Text PDF

Background: In 2020, the French Multiple Sclerosis (MS) Society (SFSEP) decided to develop a national evidence-based consensus on pregnancy in MS. As neuromyelitis optica spectrum disorders (NMOSD) shares a series of commonalities with MS, but also some significant differences, specific recommendations had to be developed.

Objectives: To establish recommendations on pregnancy in women with NMOSD.

View Article and Find Full Text PDF

Tinnitus is described as an uncomfortable sound or noise heard by an individual in the absence of an external sound source. Treating this phantom perception remains difficult even if drug and nondrug therapies are used to alleviate symptoms. The present case study aimed to investigate whether prism adaptation could induce beneficial aftereffects in a tinnitus sufferer.

View Article and Find Full Text PDF

Objective: The objective of this study was to develop evidence-based recommendations on pregnancy management for persons with multiple sclerosis (MS).

Background: MS typically affects young women in their childbearing years. Increasing evidence is available to inform questions raised by MS patients and health professionals about pregnancy issues.

View Article and Find Full Text PDF

Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort.

Neurology

January 2023

From the Univ. Bordeaux (V.P.), CNRS UMR 5293, Institut des Maladies Neurodégénératives; CHU de Bordeaux (V.P.), Pôle de Neurosciences Cliniques, Centre Mémoire de Ressources et de Recherche; Univ. Bordeaux (V.B., G.C., C.D.), Inserm U1219, PHARes Team, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED); CHU Bordeaux (V.B., G.C., C.D.), CIC 1401 EC, Pôle Santé Publique; CHU de Bordeaux (I.P.), Département d'Immunologie et d'Immunogénétique; Univ. Paris-Saclay (J.-F.M.), CEA, CNRS, Baobab UMR9027, Neurospin, CATI Multicenter Neuroimaging Platform, US52, UAR 9031, Gif-sur-Yvette; Sorbonne-Université (B.D.), Service des Maladies Cognitives et Comportementales et Institut de La Mémoire et de La Maladie d'Alzheimer (IM2A), Hôpital de La Salpêtrière, AP-PH, Paris; Univ. Toulouse (P.-J.O.), Inserm U1027, Gérontopôle, Departement de Gériatrie, CHU Purpan, Toulouse; Univ. Lille (F.P.), Inserm U1171, Centre Mémoire de Ressources et de Recherche, CHU Lille, DISTAlz, Lille; Univ. Strasbourg (F.B.), CNRS, ICube Laboratory, UMR 7357, Fédération de Médecine Translationnelle de Strasbourg, Centre Mémoire de Ressources et de Recherche, Pôle de Gériatrie, Strasbourg; Univ. Paris (C.P.), Inserm U1144, Groupe Hospitalier Lariboisière Fernand-Widal, AP-HP; Univ. Paris Cité (O.H.), EA 4468, AP-HP, Hôpitaux Universitaires Paris Centre, Service de Gériatrie, Hôpital Broca; CHU de Montpellier (K.B.), Pôle de Neurosciences, Département de Neurologie, Centre Mémoire de Ressources et de Recherche, Montpellier; Univ. Aix Marseille (M.C.), Inserm UMR 1106, Institut de Neurosciences des Systèmes, Centre Mémoire de Ressources et de Recherche, Département de Neurologie et de Neuropsychologie, AP-HM, Marseille; Univ. Angers (C.A.), UPRES EA 4638, Centre Mémoire de Ressources et de Recherche, Département de Gériatrie, CHU d'Angers, Angers; Univ. Lyon (P.K.-S.), Inserm U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon, Centre Mémoire Ressource et Recherche de Lyon (CMRR), Hôpital des Charpennes, Hospices Civils de Lyon; Univ. Picardie (O.G.), UR UPJV4559, Laboratoire de Neurosciences Fonctionnelles et Pathologies, Service de Neurologie, CHU Amiens; Univ. Normandie (D.W.), UNIROUEN, Inserm U1245, Departement de Neurologie, CNR-MAJ, CHU de Rouen; Centre Mémoire de Ressources et de Recherche Grenoble Arc Alpin (M.S.), Pôle de Psychiatrie et Neurologie, CHU Grenoble Alpes; CHU de Nantes (C.B.-B.), Département de Neurologie, Centre Mémoire de Ressources et Recherche, Nantes; Univ. Bordeaux (I.B.-M.), CNRS UMR 5536, Centre de Résonance Magnétique des Systèmes Biologiques, Pôle de Gérontologie Clinique, CHU de Bordeaux; and Univ. Clermont Auvergne (I.J.), CNRS, CHU Clermont-Ferrand, Centre Mémoire de Ressources et de Recherche, Service de Psychiatrie de L'Adulte A et Psychologie Médicale, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand.

Background And Objective: Blood biomarkers for Alzheimer disease (AD) have consistently proven to be associated with CSF or PET biomarkers and effectively discriminate AD from other neurodegenerative diseases. Our aim was to test their utility in clinical practice, from a multicentric unselected prospective cohort where patients presented with a large spectrum of cognitive deficits or complaints.

Methods: The MEMENTO cohort enrolled 2,323 outpatients with subjective cognitive complaint (SCC) or mild cognitive impairment (MCI) consulting in 26 French memory clinics.

View Article and Find Full Text PDF
Article Synopsis
  • The European task force is working on a diagnostic workflow for neurocognitive disorders in older adults, focusing on how to effectively use biomarkers despite incomplete evidence for their validity.
  • They employed a Delphi consensus method, involving 22 delegates from 11 scientific societies, to gather expert opinions and establish foundational assumptions for the workflow.
  • Preliminary results suggest a structured approach emphasizing specialized clinical settings, early-stage diagnosis (MCI-mild dementia), and specific pre-assessment screenings, setting the stage for a future comprehensive guideline that adapts with new findings.
View Article and Find Full Text PDF

Introduction: Sleep disorders are still often underestimated in patient care management even though they are present in the criteria of the American College of Rheumatology for the diagnosis of fibromyalgia syndrome (FMS). The objective of this study will be to assess the current situation of sleep disorders in patients with FMS in France and to estimate its prevalence.

Methods And Analysis: The FIBOBS study is a multicentred, prospective, observational trial performed by 46 specialised chronic pain structures in France.

View Article and Find Full Text PDF

Objectives: Sleepiness is associated with decreased cognitive abilities and remains one of the main causes of fatal road accidents. The tools currently available to assess sleepiness, such as questionnaires, are subject to intra- and inter-individual variability, while multiple sleep latency tests are only feasible in few sleep laboratories. The main objective of this study was to explore new potential markers (neurocognitive, biological) to objectively assess sleepiness in drivers.

View Article and Find Full Text PDF

Answer to September 2022 Photo Quiz.

J Clin Microbiol

September 2022

Institut des Agents Infectieux, Parasitologie Mycologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyongrid.413852.9, Lyon, France.

Read the full article for the answer.

View Article and Find Full Text PDF

Photo Quiz: Oral Finding in a 50-Year-Old Man Hospitalized for COVID-19.

J Clin Microbiol

September 2022

Institut des Agents Infectieux, Parasitologie Mycologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyongrid.413852.9, Lyon, France.

View Article and Find Full Text PDF

3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohort.

Prog Neuropsychopharmacol Biol Psychiatry

January 2023

Fondation FondaMental, Créteil, France; AP-HM, Aix-Marseille Univ, School of medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, 27 Boulevard Jean Moulin, 13005 Marseille, France. Electronic address:

Aims: Metabolic Syndrome (MetS) is a major health epidemic of Western countries and patients with schizophrenia is a particularly vulnerable population due to lifestyle, mental illness and treatment factors. However, we lack prospective data to guide prevention. The aim of our study is then to determine MetS incidence and predictors in schizophrenia.

View Article and Find Full Text PDF

Digitalized transcranial electrical stimulation: A consensus statement.

Clin Neurophysiol

November 2022

Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Article Synopsis
  • * A study investigated the readiness and barriers of tES for digital trials by gathering insights from specialists and companies, resulting in Delphi-based recommendations with a strong agreement on the benefits of tES, like safety and affordability, but also highlighting concerns about supervision and regulatory clarity.
  • * Overall, while tES holds potential for broader application in digital trials, there is a lack of consensus on addressing specific methodological biases, leading to the proposal of a framework to better integrate mobile health technologies with the
View Article and Find Full Text PDF
Article Synopsis
  • Tobacco use is prevalent among individuals with schizophrenia, and while some short-term studies suggest it may have short-term benefits, this research explores its overall impact on cognitive functioning and psychiatric characteristics in stable outpatients with schizophrenia.
  • The study involved 1233 participants, showing that over half were current smokers, with significant associations found between smoking, cognitive impairment (particularly in abstract reasoning), and higher instances of alcohol and cannabis use disorders.
  • The findings indicate that chronic smoking is linked to cognitive decline in schizophrenia patients, challenging the idea that smoking is a form of self-medication, and highlight the need for further research on the long-term effects of tobacco on cognitive development in this population.
View Article and Find Full Text PDF

Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients.

Mult Scler Relat Disord

December 2022

Neurology Department, CRCSEP, Rennes Clinical Investigation Centre CIC-P 1414, Service de Neurologie, CHU Pontchaillou, Rennes University Hospital Rennes University INSERM, Rennes 35033, France; Microenvironment, Cell Differentiation, Immunology and Cancer unit, INSERM, Rennes I University, French Blood Agency, Rennes, France. Electronic address:

Background: In Multiple Sclerosis (MS) women, therapeutic management for pregnancy planning and during pregnancy still represents a challenge regarding timing of disease-modifying therapies (DMT) stop, risk of disease reactivation and potential fetal toxicity. The objective of this study was to describe disease activity during pregnancy and postpartum depending on treatment status before conception in women with MS.

Methods: 339 MS patients who have achieved a pregnancy between 2007 and 2017 were included.

View Article and Find Full Text PDF

Introduction: The rates of alcohol and illegal drug use and the prevalence of alcohol and illegal drug use disorders (AUDs and DUDs) are high in prison populations, particularly in men entering jail. However, these rates have never been exhaustively assessed and compared to those of the general population in France.

Methods: We based our research on two surveys, conducted in the same French region, which included a total of 630 men entering jail and 5,793 men recruited from the general population.

View Article and Find Full Text PDF

Background: Ocrelizumab, a humanized anti-CD20 monoclonal antibody, has been approved in Europe for the treatment of adult patients with active relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), on the basis of previous phase III studies. However, limited data were available on ocrelizumab efficacy in RMS according to the Lublin definition of activity (clinical and/or imaging features) used in the current drug label. The PRO-MSACTIVE study was thus designed to provide additional data on ocrelizumab efficacy according to this definition, and also on safety and patient reported outcomes (PROs).

View Article and Find Full Text PDF

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.

Neurology

October 2022

From the CORe (I.R., C.M., T.K.), Department of Medicine, University of Melbourne, Australia; Melbourne MS Centre (I.R., C.M., T.K.), Department of Neurology, Royal Melbourne Hospital, Australia; Rennes, University (E.L.), EHESP, REPERES EA 7449, France; Univ Rennes (E.L.), CHU Rennes, Inserm, CIC 1414 ([Centre d'Investigation Clinique de Rennes]), France; Université de Lyon (R.C.), Université Claude Bernard Lyon 1, France; Hospices Civils de Lyon (R.C.), Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline et Neuro-inflammation, Bron, France; Observatoire Français de La Sclérose en Plaques (R.C.), Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, France; Eugène Devic EDMUS Foundation Against Multiple Sclerosis (R.C.), State-approved Foundation, Bron, France; Department of Neurology and Center of Clinical Neuroscience (D.H., E.K.H.), First Faculty of Medicine, Charles University in Prague and General University Hospital, Czech Republic; Nancy University Hospital (M.D.), Department of Neurology, Nancy, France; Université de Lorraine (M.D.), APEMAC, Nancy, France; Department of Medical and Surgical Sciences and Advanced Technologies (F.P.), GF Ingrassia, Catania, Italy; Multiple Sclerosis Center (F.P.), University of Catania, Italy; CHU de Strasbourg (J.D.S.), Department of Neurology and Clinical Investigation Center, CIC 1434, INSERM 1434, Strasbourg, France; Hospital Universitario Virgen Macarena (G.I., S.E.), Sevilla, Spain; CHU Pontchaillou (G.E.), CIC1414 INSERM, Rennes, France; CHUM MS Center and Universite de Montreal (A.P., M.G.), Canada; Dokuz Eylul University (S.O.), Konak/Izmir, Turkey; CISSS Chaudière-Appalache (P.G.), Levis, Canada; CHU Lille (H.Z.), CRCSEP Lille, Univ Lille, U1172, France; CHU de Toulouse (J.C.), Hôpital Pierre-Paul Riquet, Department of Neurology, CRC-SEP, France; Département de Neurologie (E.M.), Hôpital Pitié-Salpêtrière, APHP, Paris; CHU de Dijon (T.M.), Department of Neurology, EA4184, France; Department NEUROFARBA (M.P.A.), University of Florence, Italy; CHU de Montpellier (P.L.), MS Unit, France; University of Montpellier (MUSE) (P.L.), France; Division of Neurology (Raed Alroughani), Department of Medicine, Amiri Hospital, Sharq, Kuwait; Department of Neurology (K.B., O.S.), Box Hill Hospital, Melbourne, Australia; Monash University (K.B., O.S.), Melbourne, Australia; Melbourne MS Centre (K.B.), Royal Melbourne Hospital, Australia; The Alfred Hospital (O.S.), Melbourne, Australia; Medical Faculty (M.T.), 19 Mayis University, Samsun, Turkey; CHU de Nantes (D.A.L.), Service de Neurologie & CIC015 INSERM, France; CRTI-Inserm U1064 (D.A.L.), Nantes, France; CHU de Besançon (E.B.), Service de Neurologie 25 030 Besançon, France; Neuro Rive-Sud (F.G.M.), Quebec, Canada; Neurology (C.L.-F.), UR2CA, Centre Hospitalier Universitaire Pasteur2, Université Nice Côte d'Azur, Nice, France; UOC Neurologia (E.C.), Azienda Sanitaria Unica Regionale Marche-AV3, Macerata, Italy; KTU Medical Faculty Farabi Hospital (C.B.), Trabzon, Turkey; School of Medicine and Public Health (J.L.-S.), University Newcastle, Australia; Department of Neurology (J.L.-S.), John Hunter Hospital, Hunter New England Health, Newcastle, Australia; CHU Clermont-Ferrand (Pierre Clavelou), Department of Neurology; Université Clermont Auvergne, Inserm, Neuro-Dol, Clermont-Ferrand, France; Sorbonne Universités (B.S.), UPMC Paris 06, Brain and Spine Institute, ICM, Hôpital de La Pitié Salpêtrière, Inserm UMR S 1127, CNRS UMR 7225, and Department of Neurology, AP-HP, Saint-Antoine Hospital, Paris, France; CSSS Saint-Jérôme (Julie Prevost), Saint-Jerome, Canada; Neurologic Clinic and Policlinic (L.K.), Departments of Medicine and Clinical Research, University Hospital and University of Basel, Switzerland; Aix Marseille Univ (Jean Pelletier), APHM, Hôpital de La Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, France; Isfahan University of Medical Sciences (V.S.), Iran; Nehme and Therese Tohme Multiple Sclerosis Center (B.I.Y., S.J.K.), American University of Beirut Medical Center, Beirut, Lebanon; Department of Neurology (Oliver Gerlach), Zuyderland Medical Center, Sittard-Geleen, Netherlands; Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino (D.L.A.S.), Italy; Cliniques Universitaires Saint-Luc (V.V.P.), Université Catholique de Louvain, Brussels, Belgium; Fondation Rotschild (Olivier Gout), Department of Neurology, Paris, France; Haydarpasa Numune Training and Research Hospital (R.T.), Istanbul, Turkey; Hôpital de Poissy (O.H.), Department of Neurology, France; Department of Neurology (E.T.), Nimes University Hospital, France; Institut de Génomique Fonctionnelle (E.T.), UMR5203, INSERM 1191, Univ. Montpellier, France; University of Queensland (P.A.M.), Brisbane, Australia; Royal Brisbane and Women's Hospital (P.A.M.), Australia; Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases (A.S.), Istanbul, Turkey; CHU de Rouen (B.B.), Department of Neurology, France; Flinders University (M.S.), Adelaide, Australia; Instituto de Investigación Sanitaria Biodonostia (T.C.-T.), Hospital Universitario Donostia, San Sebastián, Spain; CHU de Reims (S.B.), Department of Neurology, France; Nemocnice Jihlava (Radek Ampapa), Czech Republic; Monash Medical Centre (E.G.B.), Melbourne, Australia; APHP (A.W.), Hôpital Henri Mondor, Department of Neurology, Créteil, France; Austin Health (R.A.M.), Melbourne, Australia; University Hospital Reina Sofia (E.A.-M.), Cordoba, Spain; CHU de La Martinique (Philippe Cabre), Department of Neurology, Fort-de-France, France; Hôpital Sud Francilien (N.H.B.), Department of Neurology, Corbeil Essonnes, France; Department of Neurology (A.V.W., H.B.), The Alfred Hospital, Melbourne, Australia; Central Clinical School (A.V.W., H.B.), Monash University, Melbourne, Australia; Department of Neurology (G.L., L.V.H.), University Hospital Ghent, Belgium; Hospital Germans Trias I Pujol (C.M.R.-T.), Badalona, Spain; CHU La Milétrie (N.M.), Hôpital Jean Bernard, Department of Neurology, Poitiers, France; Liverpool Hospital (S.H.), Sydney, Australia; Hospital de Galdakao-Usansolo (J.L.S.-M.), Spain; Brain and Mind Centre (M.H.B.), Sydney, Australia; CHU Bicêtre (C.L.), Department of Neurology, F-94275 Le Kremlin Bicêtre, France; Westmead Hospital (Steve Vucic), Sydney, Australia; Department of Neurology (Y.S., R.G.), Razi Hospital, Manouba, Tunisia; Department of Neurology (T.C.), Faculty of Medicine, University of Debrecen, Hungary; Hospital Universitari MútuaTerrassa (J.S.), Barcelona, Spain; Groene Hart Ziekenhuis (K.G.), Gouda, Netherlands; Sultan Qaboos University Hospital (A.A.-A.), Al-Khodh, Oman; Universidade Metropolitana de Santos (Y.D.F.), Santos, Brazil; Service de Neurologie (Sandra Vukusic), Sclérose en Plaques, Pathologies de La Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France; Centre des Neurosciences de Lyon (Sandra Vukusic), Observatoire Français de La Sclérose en Plaques, INSERM 1028 et CNRS UMR5292, France; and Université Claude Bernard Lyon 1 (Sandra Vukusic), Faculté de Médecine Lyon Est, France.

Article Synopsis
  • This study evaluates the rate of disease activity return in multiple sclerosis (MS) patients after they stop using disease-modifying therapy, focusing on relapse rates and factors influencing relapse.
  • A large sample of 14,213 patients showed that relapse rates typically increased within 2 months after stopping treatment, with earlier commencement of new therapy reducing these rates significantly.
  • Factors predicting relapse included having a higher relapse rate prior to stopping therapy, being younger, being female, and having a higher Expanded Disability Status Scale (EDSS) score, with subsequent therapy reducing both relapse risk and disability progression.
View Article and Find Full Text PDF

Parent history of severe mental illness (PHSMI) may have long-term consequences in adult offspring due to genetic and early environmental factors in preliminary studies. To compare the outcomes associated in subjects with PHSMI to those in patients without PHSMI. The participants with schizophrenia and schizoaffective disorders were recruited in the ongoing FACE-SZ cohort at a national level (10 expert centers) and evaluated with a 1-day-long standardized battery of clinician-rated scales and patient-reported outcomes.

View Article and Find Full Text PDF

Missense variants in ANKRD11 cause KBG syndrome by impairment of stability or transcriptional activity of the encoded protein.

Genet Med

October 2022

Department of Human Genetics, Radboudumc, Nijmegen, The Netherlands; Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands; Center of Excellence for Neuropsychiatry, Vincent van Gogh Institute for Psychiatry, Venray, The Netherlands.

Purpose: Although haploinsufficiency of ANKRD11 is among the most common genetic causes of neurodevelopmental disorders, the role of rare ANKRD11 missense variation remains unclear. We characterized clinical, molecular, and functional spectra of ANKRD11 missense variants.

Methods: We collected clinical information of individuals with ANKRD11 missense variants and evaluated phenotypic fit to KBG syndrome.

View Article and Find Full Text PDF

Most recent research highlights how a specific form of causal understanding, namely technical reasoning, may support the increasing complexity of tools and techniques developed by humans over generations, i.e., the cumulative technological culture (CTC).

View Article and Find Full Text PDF

Background: Pulmonary hypoplasia, Diaphragmatic anomalies, Anophthalmia/microphthalmia and Cardiac defects delineate the PDAC syndrome. We aim to identify the cause of PDAC syndrome in patients who do not carry pathogenic variants in and , which have been previously associated with this disorder.

Methods: We sequenced the exome of patients with unexplained PDAC syndrome and performed functional validation of candidate variants.

View Article and Find Full Text PDF

Factors associated with post-stroke social participation: A quantitative study based on the ICF framework.

Ann Phys Rehabil Med

April 2023

Université Claude Bernard Lyon 1, Research on Healthcare Performance (RESHAPE), INSERM U1290, Lyon, France; Hospices Civils de Lyon, Pôle Santé Publique, F-69008 Lyon, France.

Background: Post-stroke social participation is a major determinant of quality of life and life satisfaction. However, few data relating to participation determinants are available, especially the influence of psychological factors and factors related to the living environment.

Objectives: This study investigated determinants of post-stroke social participation within the International Classification of Functioning, Disability and Health framework.

View Article and Find Full Text PDF